Pepscan Therapeutics, a Netherlands-based biotechnology firm focusing on protein mimicry technology, has achieved two milestones in the research collaboration with Janssen R&D Ireland, formerly Tibotec Pharmaceuticals, and received undisclosed payments. 

Pepscan has discovered novel peptides with potential therapeutic utility using its proprietary peptide array platform for high throughput synthesis and screening of “conformationally stabilized” CLIPS (Chemical LInkage of Peptides onto Scaffolds) peptides.

“The achievement of these milestones demonstrates the effectiveness of our high throughput peptide array technology for the discovery of novel peptides with excellent activity and proteolytic stability,” said Wim Mol, CEO of Pepscan. “We consider this achievement a further expression of our expertise in the field of peptide lead discovery and optimization.”